Doing the exact same thing, bought a little more this morning at 2.70, and plan to add again if it falters to $2.40ish...
Thanks, and continued success to us...
Doing the exact same thing, bought a little more this morning at 2.70, and plan to add again if it falters to $2.40ish...
Thanks, and continued success to us...
I dont really want to make to0 many chart comments on PRED because as you see in the title, I have big plans for this as an investment . I have no interest in trading any of my shares as its just not worth the risk. Something could be announced overnight to change the game, and I really dont want to worry about how to get back in. That being said, yesterdays DOJI ( a closing price basically in between the high and low print, signaled a potential short term top , and the shorts ran the stops to take out what seems like, all the hot money . Most stocks like PRED who get short term overbought are prone to attacks at the end of the month, and end of the qtr . As painful as today was to my P+l, Im still a buyer so I did also add @ I believe 2.45 . Pretty normal price action, especially if it can hold that friday high of 2.35 . If not, maybe we get down to 2-2.10 are where I know there are huge buyers who will be looking for size . On the upside , 2.80 gets us back going.
The stock is a big winner, with massive upside, and the worst thing you can do is to get shaken out down here, when we haven't even gotten started . When we uplist, the big boys will come in take this one to another level
Just tell your wife you lost the passcode to the brokerage acct, and you emailed them to get it reset . You will let her know when you get it. (and it ok to check the acct )
The stock is a big winner, with massive upside, and the worst thing you can do is to get shaken out down here, when we haven't even gotten started . When we uplist, the big boys will come in take this one to another level
Just tell your wife you lost the passcode to the brokerage acct, and you emailed them to get it reset . You will let her know when you get it. (and it ok to check the acct )
Predictive Technology Group Announces Lab Expansion and New Research and Development Facility for Subsidiary, Predictive Biotech
GlobeNewswire•March 28, 2019
Four photos accompanying this announcement are available at:
http://www.globenewswire.com/NewsRoom/AttachmentNg/af5c9511-9709-4fe4-8ef7-6cbd93b0ef8c
http://www.globenewswire.com/NewsRoom/AttachmentNg/feeeda85-5b55-4c5c-8146-2d8eb8b2f814
http://www.globenewswire.com/NewsRoom/AttachmentNg/f2353467-4aa8-4532-ba30-5730a515afbe
http://www.globenewswire.com/NewsRoom/AttachmentNg/d8a3c56d-790a-4d0c-9d25-221d1ee20ce4
Expansion of ISO 7, GMP/GTP lab allows for continued scale of production to meet demand, and new R&D facility accelerates product expansion
SALT LAKE CITY, March 28, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent precision therapeutic intervention, announces it has completed the buildout of a new production laboratory and R&D facility for its subsidiary company, Predictive Biotech.
The newly renovated 22,000 square foot facility, located in Research Park on the University of Utah’s campus, features an ISO 7 cleanroom and 18 ISO 5 production hoods. The lab meets Good Manufacturing Practice (GMP) and Good Tissue Practice (GTP) requirements. Environmental testing for the new lab is completed and the lab is expected to be on-line by the first week of April. The production space previously used for the production of Predictive Biotech products will transition into a new research and product development lab headed by Predictive’s Chief Laboratory Officer Doug Schmid, PhD.
“We are very pleased with completion of the lab expansion. This new facility allows us to continue to scale to meet production and sales needs. The lab has been under construction over the past few months and we look forward to bringing it on-line next week,” said Eric Olson, CEO of Predictive Biotech.
“Our new R&D facility allows us to accelerate product development and explore new areas that will add to all of our portfolio companies,” added Bradley Robinson, CEO of Predictive Technology Group.
About Predictive Biotech, Inc.
Predictive Biotech, a Salt Lake City-based life sciences company formed in 2015, is a leader in human cell and tissue products for use in regenerative medicine. A growing national network of clinics, health systems, researchers and physicians leverage Predictive’s four main placental-derived and Wharton’s Jelly umbilical cord-derived products. Predictive Biotech’s current products are regulated by the FDA under 21 CFR part 1271 section 361 as minimally manipulated allografts intended for homologous use.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com; Predrx.com; Predictivebiotech.com; and Predictivelabs.com.
GlobeNewswire•March 28, 2019
Four photos accompanying this announcement are available at:
http://www.globenewswire.com/NewsRoom/AttachmentNg/af5c9511-9709-4fe4-8ef7-6cbd93b0ef8c
http://www.globenewswire.com/NewsRoom/AttachmentNg/feeeda85-5b55-4c5c-8146-2d8eb8b2f814
http://www.globenewswire.com/NewsRoom/AttachmentNg/f2353467-4aa8-4532-ba30-5730a515afbe
http://www.globenewswire.com/NewsRoom/AttachmentNg/d8a3c56d-790a-4d0c-9d25-221d1ee20ce4
Expansion of ISO 7, GMP/GTP lab allows for continued scale of production to meet demand, and new R&D facility accelerates product expansion
SALT LAKE CITY, March 28, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent precision therapeutic intervention, announces it has completed the buildout of a new production laboratory and R&D facility for its subsidiary company, Predictive Biotech.
The newly renovated 22,000 square foot facility, located in Research Park on the University of Utah’s campus, features an ISO 7 cleanroom and 18 ISO 5 production hoods. The lab meets Good Manufacturing Practice (GMP) and Good Tissue Practice (GTP) requirements. Environmental testing for the new lab is completed and the lab is expected to be on-line by the first week of April. The production space previously used for the production of Predictive Biotech products will transition into a new research and product development lab headed by Predictive’s Chief Laboratory Officer Doug Schmid, PhD.
“We are very pleased with completion of the lab expansion. This new facility allows us to continue to scale to meet production and sales needs. The lab has been under construction over the past few months and we look forward to bringing it on-line next week,” said Eric Olson, CEO of Predictive Biotech.
“Our new R&D facility allows us to accelerate product development and explore new areas that will add to all of our portfolio companies,” added Bradley Robinson, CEO of Predictive Technology Group.
About Predictive Biotech, Inc.
Predictive Biotech, a Salt Lake City-based life sciences company formed in 2015, is a leader in human cell and tissue products for use in regenerative medicine. A growing national network of clinics, health systems, researchers and physicians leverage Predictive’s four main placental-derived and Wharton’s Jelly umbilical cord-derived products. Predictive Biotech’s current products are regulated by the FDA under 21 CFR part 1271 section 361 as minimally manipulated allografts intended for homologous use.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com; Predrx.com; Predictivebiotech.com; and Predictivelabs.com.
[FONT="] [/FONT][FONT="]new web site [/FONT][FONT="] Predictive Biotech (wholly-owned subsidiary of PRED
[/FONT]https://www.predictivebiotech.com/
[/FONT]https://www.predictivebiotech.com/
Predictive Technology Group, Inc. (PRED~$2.13)
Corporate phone # 757 306 6090www.predtechgroup.com
www.predicttivebiotech.com
www.predictivelabs.com
Predictive Technology Group, Inc. , through its wholly owned subsidiaries , revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases onsets and progressions. PRED'S subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person's risk of disease and therapeutic products designed to effectively prevent and/or treat diseases.
Through its' wholly -owned subsidiaries, Predictive Therapeutics and Predictive Biotech, the company focuses on four main clinical categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Human Cell and Tissue Products. In addition to Predictive Biotech's efforts to advance regenerative medicine. Predictive Therapeutics is committed to assisting women in overcoming the devastating consequences of endometriosis via appropriate early-stage diagnosis and subsequent treatment.
TOTAL PRODUCTIVITY LOSS IN EMPLOYED WOMEN WITH ENDOMETRIOSIS AVERAGES 6.3 HOURS/WEEK, WITH THE MAJORITY OF LOST PRODUCTIVITY DUE TO PRESENTEEISM, AND THE YEARLY TOTAL COST OF ENDOMETRIOSIS HAS BEEN ESTIMATED AT $22 BILLION IN THE USA (APRIL 2018).
Endometriosis is a chronic, complex, yet relatively common gynecological disorder, reportedly affecting >7 0 million adult and adolescent females worldwide.
Predictive Therapeutics (PRx) and Predictive biotech, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics.
PRx utilization of molecular diagnostics focuses on the analysis of genes and their mutations to assess a patient's inherited risk for developing a particular disease and its progression. Additionally, PRx believes that advances in the emerging field of molecular diagnostics will improve the ability to determine which patients are subject to a greater risk of developing disease, and who therefore would benefit from preventive therapies. Molecular diagnostic products may also guide a patient's healthcare to ensure the patient receives the most appropriate treatment at the most appropriate time.
Current trends in medicine lie in the creation of new classes of drugs that treat the underlying cause, not just the symptoms, of disease and may be useful in disease prevention. By understanding the genetic basis of disease and by working with strategic partners, PRx believes that it will be able to develop drugs and treatment protocols that are more effective, resulting in better patient outcomes at significantly lower costs.
The first expected diagnostic PRED, through its sub PRx, expects to commercialize is a genetic diagnostic for ENDOMETRIOSIS for the fertility market. PRx then will focus development resources on its proprietary genetic based diagnostics for scoliosis and degenerative disc disease.
NHP-07- First pharma/therapeutic candidate to be developed by PRx. Management believes NHP-07 with EndoRisk** as a companion diagnostic/prognostic is the only treatment protocol that may suppress/prevent development of endometriosis and its debilitating symptoms.
Predictive biotech develops and commercializes minimally manipulated allograft products from umbilical cord and placental tissue.
HUMAN CELL AND TISSUE PRODUCTS INCLUDE:
1.CoreCyte** is a minimally manipulated human tissue allograft suspension derived from the Wharton's Jelly of the umbilical cord . CoreCyte** is processed to preserve the biological and structural integrity of Wharton's jelly for homologous use.
2.PolyCyte** is a minimally manipulated human tissue allograft suspension derived from the Wharton's jelly of the umbilical cord. PolyCyte** is processed to preserve the molecular profiles of cytokines, growth factors and proteins in Wharton's jelly for homologous use.
3.AmnioCyte Plus ** is a minimally manipulated human tissue allograft suspension derived from the extracellular matrix of the amniotic membrane. AmnioCyte Plus** is processed to preserve the cellular scaffolding proteins and cytokines in amniotic membrane for homologous use.
4. AmnioCyte** is a minimally manipulated human tissue allograft derived from amniotic fluid. AmnioCyte** is processed to preserve the molecular profile of cytokines, growth factors and proteins in amniotic fluid for homologous use.
We suggest if you want even more detailed information concerning all the additional research and development that you read the Quarterly Report (Feb 15, 2019) ending December 31, 2018. We also suggest that you visit their website and of course read the current news.
LET US TAKE A LOOK AT THE MANAGEMENT TEAM , DIRECTORS AND ADVISORY BOARD!
1.Mr, John Sorrentino~Chairman. VP and CEO of Pfizer Vaccine R&D~
2.Mr. Bradley Robinson~President. Previously President, Sagent Technologies, CEO/Co-Founder of Infusive Technologies and Director/Co-Founder of Specialized Health Products, Inc.
3. Mr. Michael Dey~Director. Executive positions at Wyeth, later acquired by Pfizer, where he was both the President and the President of Scientific Affairs for Wyeth's Women's Health Care business. As President of Wyeth's WHC for 7 years. Dr Dey managed its global resources of more than $3 billion annually.
4.Mr. Simon Brewer~CFO~Served as CFO for Norbest and played integral role in the Company's sales growth to $150 million annually.
5.Mr. Paul Evans~COO~Prior he was head of all intellectual property matters for Vivint.
6.Orrin G Hatch~7 terms as U.S. Senator(42 years) from Utah
6.Mr. Barhorst ~ Financial Advisory Board ~Chair of The California State University Foundation . He retired as President and CEO of ING Financial ,LLC
7. Mr. Jay Moyes~Director~ CFO of publicly traded biomaterials company, Amedica Corp, now SINTX Tech. Also CFO during 14 year tenure at publicly traded Myraid Genetics. Myraid transitioned from 10 to more than 900 employees,he was instrumental in raising more than $500 million in public and private finance .
8.Dr. Taylor, a Chief of Obstetrics and Gynecology at Yale (Scientific Advisory Board)
9. Dr. kenneth Ward ~Chairman and CEO of Juneau Biosciences (Scientific Advisory Board)
Note: PRED recently acquired 70% of this company. See recent presser.
10. Mr. Eric Olson~Executive VP and CEO of Predictive Biotech.~ Prior CEO of Skeletal kinetics which developed and commercialized synthetic bone substitutes for Orthopedic and Spinal applications.
11. Dr. John Nelson~Chief Medical Officer~Served as President of the AMA and served on the Advisory Committee to the Director of the National institute of Health (NIH).
12. Mr Tim Lacy~President~27 years in the healthcare industry. Key role in the commercialization of PRED products and services.
NOTE: All directors and Advisory Board members do not receive any payments for their service except for recently offered 1 year options to up to 10,000,000 shares of restricted common shares at $2.07. These option only have a one year term limit to exercise. One person does have a small amount of stock options at .50 and the balance at $2.70, but only have 1 year exercise period as well.
Select financial data:
The reporting revenue derived from HCT/Ps. The Company operates in two reportable segments. HCT/Ps and diagnostics and therapeutics. Predictive Biotech's HCT/Ps are processed in the company's FDA registered lab. This segment HCT/Ps manipulates tissue products and are prepared utilizing proprietary extraction methods that reduce the loss of important scaffolding, growth factor and general cytokines and are intended for homologous use. Predictive Technology's diagnostics and therapeutics uses data analytics for disease identification and subsequent therapeutic intervention through unique novel gene-based diagnostics, biotechnology treatments and companion therapeutics.
Revenue year-ending fiscal 18 ~ $16.2 million and net loss of $12 million.
Revenue for the 6 months ending 12/31/18 ( fiscal 19) revenues equaled $18.8 million and net loss $4.1 million. The total equity for the 6 months ending Dec 31, 2018 equaled $103 million and based upon 247 million shares outstanding. At the time of filing during Feb 2019 the outstanding shares equaled 271 million.
As of April 4, 2019 the total outstanding shares equaled 272 million. This number includes any shares used to acquire 70% of Juneau Bioscience which holds licensed technology supporting its ARTGuide** test for endometriosis and other genetic causes of infertility.
Note: Juneau had revenues not included within Dec 31, 2018 six month numbers. The stand alone revenue equaled $2.5 million for calendar year ending Dec 31, 2018 with losses of $2.4 million.
On or about March 26th 2019 PRED completes acquisition of Taueret Laboratories. The addition of CAP/CLIA lab and experienced diagnostics team form an unparalleled molecular clinical and research facility to accelerate new product development, commercialization and scale.
This $10 million dollar acquisition was paid with $1.2 million in restricted common stock and $8.5 million to be paid on or before Dec 31, 2020.
In conjunction with the acquisition, PRED invested $4.2 million in new laboratory instrumentation and resources to bolster capabilities in the 15,000 square-foot laboratory and administrative campus, which now contains all necessary infrastructure for the Company's clinical operations.
Taueret Laboratories is a privately held molecular lab focusing on human infertility , women's health, and childhood diseases and performs genetic testing using state-of-art-instrumentation.
Note: On March 28, 2019 PRED announced the completed build out of a new production lab and R&D facility for its sub company, Predictive Biotech. The newly renovated 22,000 square foot facility, located in Research Park on the University of Utah's campus, features an ISO 7 cleanroom and 18 ISO 5 production hoods.
Overview:
Management comments concerning 6 month financial reporting ending Dec 31, 2018 ( fiscal 2019). Bradley C. Robinson, CEO of PRED announced the most recent quarter of nearly $11 million, up more than three-fold from the year-ago period, marking our ninth consecutive quarter of growth. He goes on to say that it puts PRED on a run rate exceeding $40 million for fiscal 2019. In addition the company generated $2 million in positive cash flow from operations for the past 6 months that supported the further development and commercialization of proprietary genetic-based diagnostics and therapeutics. At the end of the second Q the company had $2.6 million cash on hand and no-long term debt.
Please keep in mind since that announcement was made there have been many additions to the growth profile of PRED.
We anticipate additional updates and projections from management near term.
BOTTOM-LINE: FROM ALL INDICATIONS WE ARE WITNESSING A HIGH TECH BIOTECH COMPANY BEING FORMED. THE CLUES SHOULD BE VERY EASY TO SPOT. THE MANAGEMENT TEAM, DIRECTORS AND ADVISORY BOARD INDICATES SERIOUS COMMITMENT FROM HIGHLY SUCCESSFUL INDIVIDUALS THAT APPEAR TO HAVE FORMED A VERY TIGHT-KNIT ORGANIZATION THAT HAS A WELL THOUGHT OUT PLAN TO GROW RAPIDLY INTO A REVENUE DRIVEN BIOTECH AND SCIENCE ORIENTED COMPANY. THE CONNECTIONS THAT MANAGEMENT MUST HAVE LEADS US TO BELIEVE THAT ADDITIONAL ACQUISITION ARE FORTHCOMING! WE BELIEVE THAT FILING THEIR FORM 10 TO LIST UPON THE NASDAQ IS ALSO IN THE WORKS. ONCE THIS COMPANY LISTS IT IS OBVIOUS THAT REGIONAL AND MAYBE LARGER FIRMS WILL FOLLOW THE SUCCESS OF PRED!
ONE MUST ASSUME THAT AS THIS COMPANY GROWS ADDITIONAL FUNDING WILL BE NEEDED SO IT A NATURAL ROAD MAP THAT INVESTMENT BANKING FIRMS WILL STEP UP TO PLATE.
WE BELIEVE THAT PRED IS IN THE EARLY STAGES OF EXPLOSIVE GROWTH VIA ORGANIC AND BY ACQUISITION.
ALL THE PIECES OF THIS PUZZLE HAVE BEEN SET IN MOTION AND THE VISIONARY INVESTOR TYPE SHOULD BE ABLE TO GLEEN WITH A GREAT DEGREE OF CERTAINTY THAT PRED IS ON THE LAUCH PAD!
(
We have a strong feeling that this opportunity may very well surpass all expectations during the next 3-6 months. We rate PRED with a very STRONG BUY RECOMMENDATION with potential rapid share appreciation.
WE WISH TO THANK ALL INVESTORS THAT HAVE BEEN FOLLOWING OUR STOCK RECOMMENDATIONS FOR THE PAST 35 YEARS. S. A. ADVISORY HAS ALWAYS TRIED TO BE AS HONEST AND ETHICAL WITH RESPECT TO OUR HONEST OPINION AND RECOMMENDATIONS.
WE MAY BUY, SELL AND OR HOLD AT OUR OWN DISCRETION .We currently own shares in all stocks mentioned..The reporting revenue derived from HCT/Ps. The Company operates in two reportable segments. HCT/Ps and diagnostics and therapeutics. Predictive Biotech's HCT/Ps are processed in the company's FDA registered lab. This segment HCT/Ps manipulates tissue products and are prepared utilizing proprietary extraction methods that reduce the loss of important scaffolding, growth factor and general cytokines and are intended for homologous use. Predictive Technology's diagnostics and therapeutics uses data analytics for disease identification and subsequent therapeutic intervention through unique novel gene-based diagnostics, biotechnology treatments and companion therapeutics.
Revenue year-ending fiscal 18 ~ $16.2 million and net loss of $12 million.
Revenue for the 6 months ending 12/31/18 ( fiscal 19) revenues equaled $18.8 million and net loss $4.1 million. The total equity for the 6 months ending Dec 31, 2018 equaled $103 million and based upon 247 million shares outstanding. At the time of filing during Feb 2019 the outstanding shares equaled 271 million.
As of April 4, 2019 the total outstanding shares equaled 272 million. This number includes any shares used to acquire 70% of Juneau Bioscience which holds licensed technology supporting its ARTGuide** test for endometriosis and other genetic causes of infertility.
Note: Juneau had revenues not included within Dec 31, 2018 six month numbers. The stand alone revenue equaled $2.5 million for calendar year ending Dec 31, 2018 with losses of $2.4 million.
On or about March 26th 2019 PRED completes acquisition of Taueret Laboratories. The addition of CAP/CLIA lab and experienced diagnostics team form an unparalleled molecular clinical and research facility to accelerate new product development, commercialization and scale.
This $10 million dollar acquisition was paid with $1.2 million in restricted common stock and $8.5 million to be paid on or before Dec 31, 2020.
In conjunction with the acquisition, PRED invested $4.2 million in new laboratory instrumentation and resources to bolster capabilities in the 15,000 square-foot laboratory and administrative campus, which now contains all necessary infrastructure for the Company's clinical operations.
Taueret Laboratories is a privately held molecular lab focusing on human infertility , women's health, and childhood diseases and performs genetic testing using state-of-art-instrumentation.
Note: On March 28, 2019 PRED announced the completed build out of a new production lab and R&D facility for its sub company, Predictive Biotech. The newly renovated 22,000 square foot facility, located in Research Park on the University of Utah's campus, features an ISO 7 cleanroom and 18 ISO 5 production hoods.
Overview:
Management comments concerning 6 month financial reporting ending Dec 31, 2018 ( fiscal 2019). Bradley C. Robinson, CEO of PRED announced the most recent quarter of nearly $11 million, up more than three-fold from the year-ago period, marking our ninth consecutive quarter of growth. He goes on to say that it puts PRED on a run rate exceeding $40 million for fiscal 2019. In addition the company generated $2 million in positive cash flow from operations for the past 6 months that supported the further development and commercialization of proprietary genetic-based diagnostics and therapeutics. At the end of the second Q the company had $2.6 million cash on hand and no-long term debt.
Please keep in mind since that announcement was made there have been many additions to the growth profile of PRED.
We anticipate additional updates and projections from management near term.
BOTTOM-LINE: FROM ALL INDICATIONS WE ARE WITNESSING A HIGH TECH BIOTECH COMPANY BEING FORMED. THE CLUES SHOULD BE VERY EASY TO SPOT. THE MANAGEMENT TEAM, DIRECTORS AND ADVISORY BOARD INDICATES SERIOUS COMMITMENT FROM HIGHLY SUCCESSFUL INDIVIDUALS THAT APPEAR TO HAVE FORMED A VERY TIGHT-KNIT ORGANIZATION THAT HAS A WELL THOUGHT OUT PLAN TO GROW RAPIDLY INTO A REVENUE DRIVEN BIOTECH AND SCIENCE ORIENTED COMPANY. THE CONNECTIONS THAT MANAGEMENT MUST HAVE LEADS US TO BELIEVE THAT ADDITIONAL ACQUISITION ARE FORTHCOMING! WE BELIEVE THAT FILING THEIR FORM 10 TO LIST UPON THE NASDAQ IS ALSO IN THE WORKS. ONCE THIS COMPANY LISTS IT IS OBVIOUS THAT REGIONAL AND MAYBE LARGER FIRMS WILL FOLLOW THE SUCCESS OF PRED!
ONE MUST ASSUME THAT AS THIS COMPANY GROWS ADDITIONAL FUNDING WILL BE NEEDED SO IT A NATURAL ROAD MAP THAT INVESTMENT BANKING FIRMS WILL STEP UP TO PLATE.
WE BELIEVE THAT PRED IS IN THE EARLY STAGES OF EXPLOSIVE GROWTH VIA ORGANIC AND BY ACQUISITION.
ALL THE PIECES OF THIS PUZZLE HAVE BEEN SET IN MOTION AND THE VISIONARY INVESTOR TYPE SHOULD BE ABLE TO GLEEN WITH A GREAT DEGREE OF CERTAINTY THAT PRED IS ON THE LAUCH PAD!
(
We have a strong feeling that this opportunity may very well surpass all expectations during the next 3-6 months. We rate PRED with a very STRONG BUY RECOMMENDATION with potential rapid share appreciation.
WE WISH TO THANK ALL INVESTORS THAT HAVE BEEN FOLLOWING OUR STOCK RECOMMENDATIONS FOR THE PAST 35 YEARS. S. A. ADVISORY HAS ALWAYS TRIED TO BE AS HONEST AND ETHICAL WITH RESPECT TO OUR HONEST OPINION AND RECOMMENDATIONS.
SUBSCRIPTION INFORMATION:http://www.saadvisory.com/subs/subs.htm
One Step closer to NASDQ
http://archive.fast-edgar.com//20190422/AI2A322CZ22YB2Z2222S2CDZTSWCZZI222B2/
http://archive.fast-edgar.com//20190422/AI2A322CZ22YB2Z2222S2CDZTSWCZZI222B2/
Predictive Technology Group Integrates Sales and Marketing Team from FlagshipHealth Group
GlobeNewswire•April 23, 2019
GlobeNewswire•April 23, 2019
Move Accelerates Commercialization of Subsidiary Companies’ Products
SALT LAKE CITY, April 23, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces that it has integrated the sales and marketing team from FlagshipHealth Group, a Predictive consultant contractor. This strategic move is expected to ensure control and growth of sales and marketing efforts for its subsidiary companies, Predictive Biotech and Predictive Laboratories. The integration will enable Predictive and its subsidiaries to combine their domestic direct sales and nationwide distributor network with the sales and marketing team that has joined Predictive from Flagship.
FlagshipHealth Group, a Minneapolis-based provider of strategic sales and consulting services for the healthcare industry, has worked with Predictive Technology Group subsidiary companies to provide guidance and early development of their commercialization strategies. Both Predictive Biotech and Predictive Laboratories have leveraged the collective professional network and relationship capital of FlagshipHealth Group to drive commercial sales, business development and deeper engagement of healthcare stakeholders.
“We are pleased to have the sales and marketing team join the Predictive organization as full-time employees,” said Bradley Robinson, CEO of Predictive Technology Group. “Flagship’s diligence and commitment over the past two years have assisted Predictive in building a strong national sales and distribution team in a short period of time. As we move forward to fully address important challenges, such as clinical trial research for certain indications and reimbursement strategies, we are fortunate to have a team that has demonstrated a tremendous understanding of the complexity and stakeholder diversity of Predictive’s subsidiaries and their markets.”
Michael Herbert, a seasoned marketing professional, has served as Predictive Technology Group’s Executive Vice President since January of 2017. With this integration, Herbert will no longer hold the dual role as Flagship’s Chief Marketing Officer and will focus exclusively on Predictive. In addition to his EVP duties, Hebert will serve as Chief Sales and Marketing Officer for Predictive Biotech on an interim basis.
“We are excited to have Michael join Predictive on a full-time basis, as he brings broad sales and marketing expertise in key areas of healthcare, including human cell and tissue products, molecular diagnostic technologies and patient consumerism,” said Robinson.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com; Predrx.com; Predictivebiotech.com; and Predictivelabs.com.
SALT LAKE CITY, April 23, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces that it has integrated the sales and marketing team from FlagshipHealth Group, a Predictive consultant contractor. This strategic move is expected to ensure control and growth of sales and marketing efforts for its subsidiary companies, Predictive Biotech and Predictive Laboratories. The integration will enable Predictive and its subsidiaries to combine their domestic direct sales and nationwide distributor network with the sales and marketing team that has joined Predictive from Flagship.
FlagshipHealth Group, a Minneapolis-based provider of strategic sales and consulting services for the healthcare industry, has worked with Predictive Technology Group subsidiary companies to provide guidance and early development of their commercialization strategies. Both Predictive Biotech and Predictive Laboratories have leveraged the collective professional network and relationship capital of FlagshipHealth Group to drive commercial sales, business development and deeper engagement of healthcare stakeholders.
“We are pleased to have the sales and marketing team join the Predictive organization as full-time employees,” said Bradley Robinson, CEO of Predictive Technology Group. “Flagship’s diligence and commitment over the past two years have assisted Predictive in building a strong national sales and distribution team in a short period of time. As we move forward to fully address important challenges, such as clinical trial research for certain indications and reimbursement strategies, we are fortunate to have a team that has demonstrated a tremendous understanding of the complexity and stakeholder diversity of Predictive’s subsidiaries and their markets.”
Michael Herbert, a seasoned marketing professional, has served as Predictive Technology Group’s Executive Vice President since January of 2017. With this integration, Herbert will no longer hold the dual role as Flagship’s Chief Marketing Officer and will focus exclusively on Predictive. In addition to his EVP duties, Hebert will serve as Chief Sales and Marketing Officer for Predictive Biotech on an interim basis.
“We are excited to have Michael join Predictive on a full-time basis, as he brings broad sales and marketing expertise in key areas of healthcare, including human cell and tissue products, molecular diagnostic technologies and patient consumerism,” said Robinson.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com; Predrx.com; Predictivebiotech.com; and Predictivelabs.com.
Predictive Technology Group Names Christine Seward Senior Vice President of Sales and Marketing of Predictive Laboratories
GlobeNewswire•April 25, 2019
Former Taueret Laboratories Chief Operations Officer Lesa Nelson and Director of Quality Assurance Debbie Dyckman Join Predictive Laboratories
SALT LAKE CITY, April 25, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces that Christine Seward, MS, CGC, has joined Predictive Laboratories as Senior Vice President of Sales and Marketing. Ms. Seward brings extensive experience commercializing molecular diagnostics including products in the reproductive space from her 16-year tenure at Myriad Genetics.
Predictive Laboratories also announces the appointments of Lesa Nelson as Chief Operations Officer and Debbie Dyckman as Director of Quality Assurance of Predictive Laboratories. Both Ms. Nelson and Ms. Dyckman previously served in the same capacity at Taueret Laboratories, which was acquired by Predictive in March 2019. Ms. Nelson, who has 27 years in human genetic research including more than 20 years in senior management positions, directs all operational activities and serves as the laboratory Technical Supervisor at Predictive Laboratories. Ms. Dyckman has more than 15 years of experience in clinical trials research and quality assurance and is responsible for licensing, accreditation, document control, lab safety, internal and external inspections, quality assurance reviews and audits, and CAPA management at Predictive Laboratories.
“We are delighted to attract these highly qualified professionals as we expand our genetic testing capabilities with an initial focus on human infertility and women's health,” said Bradley Robinson, CEO of Predictive Technology Group. “Christine is highly accomplished in driving the commercial growth of molecular diagnostics with a history of successfully developing and executing product launches and negotiating contracts that exceeded growth targets. Lesa and Debbie have worked with Predictive through our prior relationship with Taueret Laboratories and bring direct, proven expertise that will be invaluable in the expansion of our state-of-the-art laboratory operations.”
Ms. Seward served in various positions with increasing responsibility at Myriad Genetics, most recently as Senior Strategic Product Director – Payer Markets. In this position, she was responsible for collaborating and aligning with a cross-functional team to develop peer-reviewed publications and developing innovative study designs to demonstrate the clinical validity, utility and cost-effectiveness of Myriad products including for reproductive health. Among prior positions at Myriad, she served as Director of Elevate 2020; Director of Marketing, Oncology Biomarkers; Senior Sales Representation; and Medical Specialist. Prior to joining Myriad, Ms. Seward was an oncology genetic counselor at the University of Virginia Health System. Ms. Seward received a Master of Science in Genetic Counseling from California State University, Northridge, and is board certified by the American Board of Genetic Counseling.
Ms. Nelson previously was Vice President of Clinical Operations for Axial, Biotech, Inc., a company focused on developing and commercializing genetic tests and treatment solutions for spinal disorders. Ms. Nelson is an active member of the American Association of Human Genetics (ASHG), the American Association of Blood Banks (AABB) and the Association of Molecular Pathologists (AMP). She has authored or co-authored more than 40 human genetics-related articles and scientific papers published in various peer-reviewed medical periodicals, and is a named inventor in three U.S. patents and five published U.S. patent applications related to the diagnosis and prognosis of human genetic conditions.
Ms. Dyckman previously served as Quality Assurance Supervisor at Affiliated Genetic and at Axial Biotech. In these prior positions, she was responsible for controlling standard operating procedures, and managing licenses and accreditations. Before that she was a Site Start-up Specialist at Quintiles (now IQVIA), where she was responsible for negotiating contracts and budgets, and guiding sites through their scientific review and approval processes. She graduated from the Medical Technology Program at Utah State University, the Lab Tech program at Claremont Mesa College and the Clinical Trial Research – AAS program at Durham Technical Community College.
About Predictive Laboratories, Inc.
Predictive Laboratories owns significant next-generation sequencing and genotyping assets along with extensive protocols, quality and laboratory management systems and other resources required by a “high complexity” molecular diagnostic laboratory operating under the Clinical Laboratory Improvement Act (CLIA). The group recently launched its novel test for women experiencing infertility, called ARTGuide™, to selected Beta launch centers. ARTGuide™ is a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other health concerns, in 2018. The test is expected to change the way that Advanced Reproductive Technologies (ART), such as in vitro fertilization (IVF), are used to assist couples having difficulty conceiving a pregnancy.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com; Predrx.com; Predictivebiotech.com; and Predictivelabs.com.
For more information, visit towww.predtechgroup.com or contact Investor Relations:
LHA Investor Relations
Jody Cain jcain@lhai.com
Kevin Mc Cabe kmccabe@lhai.com
310-691-7100
GlobeNewswire•April 25, 2019
Former Taueret Laboratories Chief Operations Officer Lesa Nelson and Director of Quality Assurance Debbie Dyckman Join Predictive Laboratories
SALT LAKE CITY, April 25, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces that Christine Seward, MS, CGC, has joined Predictive Laboratories as Senior Vice President of Sales and Marketing. Ms. Seward brings extensive experience commercializing molecular diagnostics including products in the reproductive space from her 16-year tenure at Myriad Genetics.
Predictive Laboratories also announces the appointments of Lesa Nelson as Chief Operations Officer and Debbie Dyckman as Director of Quality Assurance of Predictive Laboratories. Both Ms. Nelson and Ms. Dyckman previously served in the same capacity at Taueret Laboratories, which was acquired by Predictive in March 2019. Ms. Nelson, who has 27 years in human genetic research including more than 20 years in senior management positions, directs all operational activities and serves as the laboratory Technical Supervisor at Predictive Laboratories. Ms. Dyckman has more than 15 years of experience in clinical trials research and quality assurance and is responsible for licensing, accreditation, document control, lab safety, internal and external inspections, quality assurance reviews and audits, and CAPA management at Predictive Laboratories.
“We are delighted to attract these highly qualified professionals as we expand our genetic testing capabilities with an initial focus on human infertility and women's health,” said Bradley Robinson, CEO of Predictive Technology Group. “Christine is highly accomplished in driving the commercial growth of molecular diagnostics with a history of successfully developing and executing product launches and negotiating contracts that exceeded growth targets. Lesa and Debbie have worked with Predictive through our prior relationship with Taueret Laboratories and bring direct, proven expertise that will be invaluable in the expansion of our state-of-the-art laboratory operations.”
Ms. Seward served in various positions with increasing responsibility at Myriad Genetics, most recently as Senior Strategic Product Director – Payer Markets. In this position, she was responsible for collaborating and aligning with a cross-functional team to develop peer-reviewed publications and developing innovative study designs to demonstrate the clinical validity, utility and cost-effectiveness of Myriad products including for reproductive health. Among prior positions at Myriad, she served as Director of Elevate 2020; Director of Marketing, Oncology Biomarkers; Senior Sales Representation; and Medical Specialist. Prior to joining Myriad, Ms. Seward was an oncology genetic counselor at the University of Virginia Health System. Ms. Seward received a Master of Science in Genetic Counseling from California State University, Northridge, and is board certified by the American Board of Genetic Counseling.
Ms. Nelson previously was Vice President of Clinical Operations for Axial, Biotech, Inc., a company focused on developing and commercializing genetic tests and treatment solutions for spinal disorders. Ms. Nelson is an active member of the American Association of Human Genetics (ASHG), the American Association of Blood Banks (AABB) and the Association of Molecular Pathologists (AMP). She has authored or co-authored more than 40 human genetics-related articles and scientific papers published in various peer-reviewed medical periodicals, and is a named inventor in three U.S. patents and five published U.S. patent applications related to the diagnosis and prognosis of human genetic conditions.
Ms. Dyckman previously served as Quality Assurance Supervisor at Affiliated Genetic and at Axial Biotech. In these prior positions, she was responsible for controlling standard operating procedures, and managing licenses and accreditations. Before that she was a Site Start-up Specialist at Quintiles (now IQVIA), where she was responsible for negotiating contracts and budgets, and guiding sites through their scientific review and approval processes. She graduated from the Medical Technology Program at Utah State University, the Lab Tech program at Claremont Mesa College and the Clinical Trial Research – AAS program at Durham Technical Community College.
About Predictive Laboratories, Inc.
Predictive Laboratories owns significant next-generation sequencing and genotyping assets along with extensive protocols, quality and laboratory management systems and other resources required by a “high complexity” molecular diagnostic laboratory operating under the Clinical Laboratory Improvement Act (CLIA). The group recently launched its novel test for women experiencing infertility, called ARTGuide™, to selected Beta launch centers. ARTGuide™ is a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other health concerns, in 2018. The test is expected to change the way that Advanced Reproductive Technologies (ART), such as in vitro fertilization (IVF), are used to assist couples having difficulty conceiving a pregnancy.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com; Predrx.com; Predictivebiotech.com; and Predictivelabs.com.
For more information, visit towww.predtechgroup.com or contact Investor Relations:
LHA Investor Relations
Jody Cain jcain@lhai.com
Kevin Mc Cabe kmccabe@lhai.com
310-691-7100
Predictive Technology Group Completes Integration of Taueret Laboratories and Inception Dx into its Subsidiary, Predictive Laboratories
EmailPrint FriendlyShare
April 30, 2019 09:00 ET|Source:Predictive Technology Group, Inc.
“The integration of the Taueret Laboratories team into Predictive Laboratories was completed much faster than anticipated,” said Bradley Robinson, CEO of Predictive Technology Group. “I am excited to have this highly experienced team working to create a leading state-of-the-art laboratory in reproductive health.”
In addition to his position as CEO of Juneau Biosciences, Kenneth Ward, M.D. will assume the role of Laboratory Director of Predictive Laboratories. Dr. Ward is Board Certified in four specialties including Obstetrics and Gynecology, Maternal-Fetal Medicine, Medical Genetics and Molecular Genetics. Dr. Ward has run DNA diagnostic laboratories for 33 years and is internationally known in the field of Human Genetics. Predictive previously licensed endometriosis-related diagnostic intellectual property from Juneau on which Dr. Ward is an inventor.
Paul Evans, JD, MBA, will serve as interim CEO of Predictive Laboratories in addition to his positon as Chief Operating Officer of Predictive Technology Group. He brings more than 20 years of experience in business and corporate development roles and has been a trusted advisor to boards of directors, executive management teams and investors throughout his career with a variety of small to large private and public healthcare and technology companies.
Justine Coppinger, M.S., a Board-Certified Genetic Counselor, serves as Director of Clinical Affairs of Predictive Laboratories, bringing more than 20 years of experience in clinical and diagnostic laboratory settings. Ms. Coppinger previously served in management roles at Taueret, Assuragen, and Signature Genomics, the first commercial clinical laboratory to introduce microarray molecular cytogenetics testing.
Rakesh Chettier, M.S. will serve as Director of Bioinformatics. He brings more than 13 years of industry experience and a strong track record of scientific publications and issued patents.
As announced last week, Christine Seward, MS, CGC, joins Predictive Laboratories as Senior Vice President of Sales and Marketing. Ms. Seward brings extensive experience commercializing molecular diagnostics including products in the reproductive space from her 18-year tenure at Myriad Genetic Laboratories. Lesa Nelson serves as Chief Operations Officer and has more than 30 years of experience in Human Molecular Genetics. Debbie Dyckman will serve as Director of Quality Assurance.
Predictive Laboratories voluntarily participates in proficiency testing programs and adheres to strict accreditation standards and practices of the College of American Pathologists (CAP), the Clinical Laboratory Improvement Amendments of ‘88 (CLIA), and all applicable state licensing.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com; Predrx.com; Predictivebiotech.com; and Predictivelabs.com.
Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
Contact:
For more information, visit towww.predtechgroup.com or contact Investor Relations:
LHA Investor Relations
Jody Cain jcain@lhai.com
Kevin Mc Cabe kmccabe@lhai.com
310-691-7100
EmailPrint FriendlyShare
April 30, 2019 09:00 ET|Source:Predictive Technology Group, Inc.
SALT LAKE CITY, April 30, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces that it has completed the integration of two acquired DNA laboratories into the Predictive subsidiary, Predicative Laboratories. Predictive announced the acquisitions of CLIA-approved Taueret Laboratories in March 2019 and Inception Dx in September 2018.
Based in Salt Lake City, Predictive Laboratories runs a state-of-the-art molecular laboratory initially focusing on human infertility and women's health. Twenty-three skilled employees are performing high-complexity, proprietary laboratory tests. Predictive Laboratories recently purchased $6 million in new genomics equipment and supplies to expand the technical capabilities and capacities. Lab renovation will begin immediately to improve workflow efficiency. The laboratory’s new Federal CLIA number became effective today (46D1077919).
“The integration of the Taueret Laboratories team into Predictive Laboratories was completed much faster than anticipated,” said Bradley Robinson, CEO of Predictive Technology Group. “I am excited to have this highly experienced team working to create a leading state-of-the-art laboratory in reproductive health.”
In addition to his position as CEO of Juneau Biosciences, Kenneth Ward, M.D. will assume the role of Laboratory Director of Predictive Laboratories. Dr. Ward is Board Certified in four specialties including Obstetrics and Gynecology, Maternal-Fetal Medicine, Medical Genetics and Molecular Genetics. Dr. Ward has run DNA diagnostic laboratories for 33 years and is internationally known in the field of Human Genetics. Predictive previously licensed endometriosis-related diagnostic intellectual property from Juneau on which Dr. Ward is an inventor.
Paul Evans, JD, MBA, will serve as interim CEO of Predictive Laboratories in addition to his positon as Chief Operating Officer of Predictive Technology Group. He brings more than 20 years of experience in business and corporate development roles and has been a trusted advisor to boards of directors, executive management teams and investors throughout his career with a variety of small to large private and public healthcare and technology companies.
Justine Coppinger, M.S., a Board-Certified Genetic Counselor, serves as Director of Clinical Affairs of Predictive Laboratories, bringing more than 20 years of experience in clinical and diagnostic laboratory settings. Ms. Coppinger previously served in management roles at Taueret, Assuragen, and Signature Genomics, the first commercial clinical laboratory to introduce microarray molecular cytogenetics testing.
Rakesh Chettier, M.S. will serve as Director of Bioinformatics. He brings more than 13 years of industry experience and a strong track record of scientific publications and issued patents.
As announced last week, Christine Seward, MS, CGC, joins Predictive Laboratories as Senior Vice President of Sales and Marketing. Ms. Seward brings extensive experience commercializing molecular diagnostics including products in the reproductive space from her 18-year tenure at Myriad Genetic Laboratories. Lesa Nelson serves as Chief Operations Officer and has more than 30 years of experience in Human Molecular Genetics. Debbie Dyckman will serve as Director of Quality Assurance.
Predictive Laboratories voluntarily participates in proficiency testing programs and adheres to strict accreditation standards and practices of the College of American Pathologists (CAP), the Clinical Laboratory Improvement Amendments of ‘88 (CLIA), and all applicable state licensing.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com; Predrx.com; Predictivebiotech.com; and Predictivelabs.com.
Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
Contact:
For more information, visit towww.predtechgroup.com or contact Investor Relations:
LHA Investor Relations
Jody Cain jcain@lhai.com
Kevin Mc Cabe kmccabe@lhai.com
310-691-7100
https://insiderfinancial.com/predic...w-highs/178702/amp/?__twitter_impression=true
Predictive Technology Group Inc (OTCMKTS: PRED) Eyes New Highs After Minor Correction
Jim Bloom
![>](http://www.therxforum.com/data:image/svg+xml;charset=utf-8,<svg height="450px" width="800px" xmlns="<a href=http://www.w3.org/2000/svg" target=_blank>http://www.w3.org/2000/svg"</a> version="1.1"/>)
Predictive Technology Group
Predictive Technology Group Inc (OTCMKTS: PRED) is eyeing further gains after a pullback from this year highs. After a minor correction at the end of the first quarter, the stock has once again started rallying on the back of high turnover in traded shares.
PRED Catalysts And Price Analysis
A spike in share price and market activity follows the completion of Taueret Laboratories acquisition at the end of March. With the acquisition, the company is well positioned to strengthen its molecular clinical and research capabilities further as it seeks to accelerate new product development.
In the recent past, the company has also confirmed the expansion of a new research and development facility on the University of Utah’s campus. Predictive Technology has also integrated sales and marketing team of its FlagshipHealth Group as it seeks to ensure control and growth of its sales and marketing efforts.
The stock taking off in response to recent developments does not come as a surprise. With the short-term momentum turning bullish, Predictive Technology could as well be on its way to 52-week highs of $3.08 level.
![>](http://www.therxforum.com/data:image/svg+xml;charset=utf-8,<svg height="335px" width="579px" xmlns="<a href=http://www.w3.org/2000/svg" target=_blank>http://www.w3.org/2000/svg"</a> version="1.1"/>)
PRED Daily Chart
Standing in the way of Predictive Technology, powering high after the recent pullback is the $3 technical resistance level. A violation of the resistance level should reaffirm the stock’s breakout credentials, setting the stage for further rallies.
Conversely, failure to breach the $3 resistance level could see price action activity limited to a range of between $3 and $2, as has been the case in recent weeks.
What Does Predictive Technology Do?
Predictive Technology is engaged in the development and commercialization of discoveries and technologies, involved in molecular diagnostic and pharmaceutical therapeutic. The company’s primary goal is to revolutionize patient care through predictive data analytics and novel gene-based diagnostics.
Taueret Acquisition
After a short period of consolidation, Predictive Technology has started surging as investors react to a string of positive developments set to strengthen the company’s core business. The acquisition of clinical and research molecular laboratory Taueret Laboratories for $9.4 million and $1.2 million in the form of restrictive common stock is one of the reasons why the stock is flying high.
With the acquisition, Predictive Technology gains access to a highly experienced staff supported by an unparalleled molecular clinical and research facility.
Predictive Technology has also completed a build-out of a new production laboratory and R&D facility for its subsidiary, Predictive Biotech as part of the expansion drive. The refurbished 22,000 square foot facility will now feature ISO 7 cleanroom and 18 ISO production hoods.
Commercialization Push
The expansion paves the way for Predictive Technology to scale in a bid to meet production and sales needs. The expanded Laboratory facility should also allow the company to accelerate product development as it also explores new areas that will add to the current portfolio of companies.
Predictive Technology has since integrated its sales and marketing teams as it seeks to accelerate sales efforts across all its subsidiaries. The integration has mostly targeted FlagshipHealth Group, a Minneapolis set based strategic sales and consulting services firm.
Predictive Technology is an interesting pick as it continues to send shockwaves as a leader on the use of data analytics for disease identification. The company has completed a string of acquisitions that strengthen its prospects in the sector.
Expansion and integration of sales and marketing teams pave the way for the company to generate significant value as it moves to market its products. The stock spiking higher after a recent pullback could as well signal renewed investor interest. As it stands, Predictive Technology remains well supported for further upside action.
We will be updating our subscribers as soon as we know more. For the latest updates on PRED, sign up below!
Disclosure: We have no position in PRED and have not been compensated for this article.
Predictive Technology Group Inc (OTCMKTS: PRED) Eyes New Highs After Minor Correction
60 mins ago
Predictive Technology Group Inc (OTCMKTS: PRED) is eyeing further gains after a pullback from this year highs. After a minor correction at the end of the first quarter, the stock has once again started rallying on the back of high turnover in traded shares.
PRED Catalysts And Price Analysis
A spike in share price and market activity follows the completion of Taueret Laboratories acquisition at the end of March. With the acquisition, the company is well positioned to strengthen its molecular clinical and research capabilities further as it seeks to accelerate new product development.
In the recent past, the company has also confirmed the expansion of a new research and development facility on the University of Utah’s campus. Predictive Technology has also integrated sales and marketing team of its FlagshipHealth Group as it seeks to ensure control and growth of its sales and marketing efforts.
The stock taking off in response to recent developments does not come as a surprise. With the short-term momentum turning bullish, Predictive Technology could as well be on its way to 52-week highs of $3.08 level.
Standing in the way of Predictive Technology, powering high after the recent pullback is the $3 technical resistance level. A violation of the resistance level should reaffirm the stock’s breakout credentials, setting the stage for further rallies.
Conversely, failure to breach the $3 resistance level could see price action activity limited to a range of between $3 and $2, as has been the case in recent weeks.
What Does Predictive Technology Do?
Predictive Technology is engaged in the development and commercialization of discoveries and technologies, involved in molecular diagnostic and pharmaceutical therapeutic. The company’s primary goal is to revolutionize patient care through predictive data analytics and novel gene-based diagnostics.
Taueret Acquisition
After a short period of consolidation, Predictive Technology has started surging as investors react to a string of positive developments set to strengthen the company’s core business. The acquisition of clinical and research molecular laboratory Taueret Laboratories for $9.4 million and $1.2 million in the form of restrictive common stock is one of the reasons why the stock is flying high.
With the acquisition, Predictive Technology gains access to a highly experienced staff supported by an unparalleled molecular clinical and research facility.
“We plan the immediate use of our laboratory to develop a suite of new clinical tests for the reproductive health market. We expect this newly acquired laboratory to accelerate the commercialization of our current tests and provide additional capacity as our tests gain momentum,” said Bradley C. Robinson, CEO of Predictive Technology Group.
Following the acquisition, Predictive Technology has invested $4.2 million to enhance the 15,000 square foot Laboratory instrumentation, to support a wide array of clinical operations.
Predictive Technology has also completed a build-out of a new production laboratory and R&D facility for its subsidiary, Predictive Biotech as part of the expansion drive. The refurbished 22,000 square foot facility will now feature ISO 7 cleanroom and 18 ISO production hoods.
Commercialization Push
The expansion paves the way for Predictive Technology to scale in a bid to meet production and sales needs. The expanded Laboratory facility should also allow the company to accelerate product development as it also explores new areas that will add to the current portfolio of companies.
Predictive Technology has since integrated its sales and marketing teams as it seeks to accelerate sales efforts across all its subsidiaries. The integration has mostly targeted FlagshipHealth Group, a Minneapolis set based strategic sales and consulting services firm.
“As we move forward to fully address important challenges, such as clinical trial research for certain indications and reimbursement strategies, we are fortunate to have a team that has demonstrated a tremendous understanding of the complexity and stakeholder diversity of Predictive subsidiaries and their markets,” explained Mr. Robinson.
Bottom Line
Predictive Technology is an interesting pick as it continues to send shockwaves as a leader on the use of data analytics for disease identification. The company has completed a string of acquisitions that strengthen its prospects in the sector.
Expansion and integration of sales and marketing teams pave the way for the company to generate significant value as it moves to market its products. The stock spiking higher after a recent pullback could as well signal renewed investor interest. As it stands, Predictive Technology remains well supported for further upside action.
We will be updating our subscribers as soon as we know more. For the latest updates on PRED, sign up below!
Disclosure: We have no position in PRED and have not been compensated for this article.
Predictive Technology Group Submits Application to List on NASDAQ
GlobeNewswire•May 2, 2019
GlobeNewswire•May 2, 2019
SALT LAKE CITY, May 02, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces submission of its application to list its common stock on NASDAQ.
The Company’s management has completed the application and submitted the request to list Predictive on The NASDAQ Exchange. The listing of the Company’s common shares remains subject to the approval of NASDAQ and the satisfaction of all applicable listing standards.
As more information becomes available, Predictive will update the process on its intended up-listing accordingly.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com, Predrx.com, Predictivebiotech.com, and Predictivelabs.com.
The Company’s management has completed the application and submitted the request to list Predictive on The NASDAQ Exchange. The listing of the Company’s common shares remains subject to the approval of NASDAQ and the satisfaction of all applicable listing standards.
As more information becomes available, Predictive will update the process on its intended up-listing accordingly.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com, Predrx.com, Predictivebiotech.com, and Predictivelabs.com.
In for several thousand more at $2.49. Let’s Roll...
Predictive Technology Group Announces Enrollment Milestone of 200 Participants in Predictive Laboratories’ Study for Chronic Joint and Spine Pain
GlobeNewswire•May 7, 2019
GlobeNewswire•May 7, 2019
SALT LAKE CITY, May 07, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent precision therapeutic intervention, announces its wholly owned subsidiary Predictive Laboratories has reached an enrollment milestone of 200 participants in its ongoing Institutional Review Board (IRB)-approved study of spine and joint disease leading to chronic pain.
The primary objective of the IRB study is to conduct genetic research related to healthcare advancement in the diagnosis, treatment and prevention of conditions causing chronic pain. The first 200 participants have volunteered for the study by submitting their DNA samples to the Predictive Biorepository and by reporting detailed medical information through their healthcare providers.
“One in five American adults suffer with chronic pain and the use of opioids to address pain has led to an epidemic of addiction and overdose as sufferers attempt to find relief,” said Bradley Robinson, CEO of Predictive Technology Group. “Patients have embraced the opportunity to enroll in this research study and participate in the search for a better solution to chronic pain. The Predictive Biorepository’s genetic and analytic capabilities are expected to add to an already robust pipeline of genetic data that will assist in the ongoing discovery of diagnostic tests and therapeutic treatments for disease.”
“We are excited about achieving this initial milestone as we work to build a foundation for the advancement of medicine to solve real problems for real people,” said Rick W. Obray, M.D., Chairman of Predictive’s Clinical Advisory Board. “Establishing these genetic building blocks is truly how the promise of personalized medicine will move toward reality.”
Predictive Laboratories, Inc. is the sponsor of the study. Kenneth Ward, MD, Laboratory Director of Predictive Laboratories, serves as Principal Investigator.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com; Predrx.com; Predictivebiotech.com; and Predictivelabs.com.
About Predictive Laboratories, Inc.
Predictive Laboratories owns significant next-generation sequencing and genotyping assets along with extensive protocols, quality and laboratory management systems and other resources required by a “high complexity” molecular diagnostic laboratory operating under the Clinical Laboratory Improvement Act (CLIA). The group recently launched its novel test for women experiencing infertility, called ARTGuide®, to selected Beta launch centers. ARTGuide™ is a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other health concerns, in 2018. The test is expected to change the way that Advanced Reproductive Technologies (ART), such as in vitro fertilization (IVF), are used to assist couples having difficulty conceiving a pregnancy.
Forward-Looking Statements:
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
Contact:
For more information, contact Investor Relations:
LHA Investor Relations
Jody Cain jcain@lhai.com
Kevin Mc Cabe kmccabe@lhai.com
310-691-7100
The primary objective of the IRB study is to conduct genetic research related to healthcare advancement in the diagnosis, treatment and prevention of conditions causing chronic pain. The first 200 participants have volunteered for the study by submitting their DNA samples to the Predictive Biorepository and by reporting detailed medical information through their healthcare providers.
“One in five American adults suffer with chronic pain and the use of opioids to address pain has led to an epidemic of addiction and overdose as sufferers attempt to find relief,” said Bradley Robinson, CEO of Predictive Technology Group. “Patients have embraced the opportunity to enroll in this research study and participate in the search for a better solution to chronic pain. The Predictive Biorepository’s genetic and analytic capabilities are expected to add to an already robust pipeline of genetic data that will assist in the ongoing discovery of diagnostic tests and therapeutic treatments for disease.”
“We are excited about achieving this initial milestone as we work to build a foundation for the advancement of medicine to solve real problems for real people,” said Rick W. Obray, M.D., Chairman of Predictive’s Clinical Advisory Board. “Establishing these genetic building blocks is truly how the promise of personalized medicine will move toward reality.”
Predictive Laboratories, Inc. is the sponsor of the study. Kenneth Ward, MD, Laboratory Director of Predictive Laboratories, serves as Principal Investigator.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com; Predrx.com; Predictivebiotech.com; and Predictivelabs.com.
About Predictive Laboratories, Inc.
Predictive Laboratories owns significant next-generation sequencing and genotyping assets along with extensive protocols, quality and laboratory management systems and other resources required by a “high complexity” molecular diagnostic laboratory operating under the Clinical Laboratory Improvement Act (CLIA). The group recently launched its novel test for women experiencing infertility, called ARTGuide®, to selected Beta launch centers. ARTGuide™ is a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other health concerns, in 2018. The test is expected to change the way that Advanced Reproductive Technologies (ART), such as in vitro fertilization (IVF), are used to assist couples having difficulty conceiving a pregnancy.
Forward-Looking Statements:
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
Contact:
For more information, contact Investor Relations:
LHA Investor Relations
Jody Cain jcain@lhai.com
Kevin Mc Cabe kmccabe@lhai.com
310-691-7100
The breakout was 3.08. That was battle tested today as the shorts desperately wanted to close it below, and got run over . I wouldn't try and be too cute, the news flow is going to pick up and there are institutional buyers in the stock now . Just look at the volume
It was on Harry Boxers report released this morning . His targets are 3.85, then 4.5 https://www.thetechtrader.com/chart...stocktwits&utm_medium=social&utm_campaign=COD
